Otsuka to Host Web Briefing on Tolvaptan Phase 3 Trial Results in Polycystic Kidney Disease
27 Ottobre 2017 - 02:00PM
Business Wire
Otsuka Pharmaceutical Co., Ltd. (OPCJ) and its affiliate Otsuka
Pharmaceutical Development & Commercialization, Inc. (OPDC) are
pleased to invite investors and media to a November 4 web briefing
on in-depth results from the REPRISE phase 3 trial for tolvaptan, a
drug candidate for the treatment of patients in the U.S. with
autosomal dominant polycystic kidney disease (ADPKD).
Webinar briefing for investors and
media on November 4 at 7 PM, US Central Daylight Time
Agenda
●
Welcome, introductions and overview (5 min.) Robert McQuade,
Ph.D., executive vice president/chief strategic officer, OPDC
●
About ADPKD and Tolvaptan (15 min.) Frank Czerwiec, M.D., Ph.D.,
vice president, Global Clinical Development, OPDC
●
REPRISE phase 3 data (20 min.) Ronald Perrone, M.D., scientific
director, Clinical and Translational Research Center and associate
chief, Division of Nephrology, Tufts Medical Center, Boston, MA,
and a member of the Phase 3 REPRISE trial Steering Committee
●
Q&A (20 min.)
To participate in the web briefing, kindly pre-register
at:http://event.on24.com/wcc/r/1534382-1/77E66445B009CE3491DBB035504DCF69
Confirmation of registration and information on how to access
the web briefing on November 4 will be sent to registrants by
email.
An archived version of the webcast will be accessible on the
website of Otsuka Pharmaceutical Company’s parent company, Otsuka
Holdings Co., Ltd., within 24 hours after the web briefing.
The REPRISE phase 3 trial data will also be presented earlier in
the day on November 4 in a late breaking oral abstract session at
American Society of Nephrology (ASN) Kidney Week 2017, in New
Orleans (Abstract# SA-OR128). Attendees of Kidney Week 2017 are
invited to attend the session, between 10:30 AM and 12:30 PM in
Hall J.
The REPRISE trial was completed to supply confirmatory data to
the previous studyi to address the Complete Response Letter issued
by the U.S. FDA in 2013 for a New Drug Application for tolvaptan in
the treatment of adults with ADPKD.
About TolvaptanTolvaptan is a selective vasopressin
V2-receptor antagonist. By selectively blocking vasopressin at the
V2-receptor, tolvaptan has been shown to decrease cyst-cell
proliferation and fluid secretion in subjects with ADPKD,
ultimately reducing cyst development.ii In a previous Phase 3
clinical trial, tolvaptan was associated with reduced kidney growth
and slowed decline of kidney function.i
About OtsukaOtsuka Pharmaceutical Company is a global
healthcare company with the corporate philosophy: “Otsuka–people
creating new products for better health worldwide.”
All Otsuka stories start by taking the road less travelled.
Learn more about Otsuka at www.otsuka.co.jp/en/ and connect with us
in the US on LinkedIn and Twitter at @OtsukaUS.
i
Torres VE, Harris PC et al. Tolvaptan in patients with
autosomal dominant polycystic kidney disease. NEJM. 2012;367 (25):
2407-2418
ii
Reif, GA, Yamaguchi, T et al. Tolvaptan inhibits ERK-dependent cell
proliferation, Cl – secretion, and in vitro cyst growth of human
ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol;
2011; 301:F1005-F1013
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171027005212/en/
Otsuka Contacts:Media Outside
U.S.Otsuka Pharmaceutical Co, Ltd.Jeffrey Gilbert, 81
3-6361-7379Leader, Pharmaceutical
PRgilbert.jeffrey@otsuka.co.jporMedia in
U.S.Otsuka America Pharmaceutical, Inc.Melanie Deck, 1
609-535-9132Corporate
Communicationsmelanie.deck-cw@otsuka-us.comorInvestorsOtsuka Holdings Co., Ltd.Yoko
Ishii, 81 3-6361-7411Ishiiyo@Otsuka.jporTufts University
Medical Center Contact:Jeremy Lechan, 1 617-636-0104Senior
Specialist, Media Relations and
Communicationsjlechan@tuftsmedicalcenter.org